Portal de Periódicos da CAPES

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

2017; Elsevier BV; Volume: 18; Issue: 7 Linguagem: Inglês

10.1016/s1470-2045(17)30404-7

1474-5488

David Cameron, James P. Morden, Peter Canney, Galina Velikova, Robert E. Coleman, John M.S. Bartlett, Rajiv K. Agrawal, Jane Banerji, Gianfilippo Bertelli, David Bloomfield, Adrian Murray Brunt, Helena Earl, Peter Ellis, Claire Gaunt, Alexa Gillman, Nicholas Hearfield, Robert Laing, Nicholas Murray, Niki Couper, Robert C. Stein, Mark Verrill, Andrew Wardley, Peter Barrett‐Lee, Judith M. Bliss,

Breast Lesions and Carcinomas

Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve time to tumour recurrence (TTR); and whether use of oral capecitabine instead of cyclophosphamide would be non-inferior in terms of patients' outcomes and would improve toxicity, quality of life, or both.